|
US5976832A
(en)
*
|
1995-03-06 |
1999-11-02 |
Tonen Corporation |
DNA encoding novel calcium-binding proteins
|
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
|
US6685940B2
(en)
*
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
|
EE04817B1
(et)
*
|
1996-05-24 |
2007-04-16 |
Biogen, Incorporated |
Kudede regeneratsiooni modulaatorid
|
|
US6991790B1
(en)
*
|
1997-06-13 |
2006-01-31 |
Genentech, Inc. |
Antibody formulation
|
|
US6171586B1
(en)
*
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
|
ES2396693T3
(es)
*
|
1998-04-02 |
2013-02-25 |
Xintela Ab |
Heterodímero de integrina y subunidad del mismo
|
|
US20030055231A1
(en)
*
|
1998-10-28 |
2003-03-20 |
Jian Ni |
12 human secreted proteins
|
|
US6914128B1
(en)
*
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
|
US7883704B2
(en)
*
|
1999-03-25 |
2011-02-08 |
Abbott Gmbh & Co. Kg |
Methods for inhibiting the activity of the P40 subunit of human IL-12
|
|
CA2365601A1
(en)
*
|
1999-03-29 |
2000-10-05 |
Kansai Technology Licensing Organization Co., Ltd. |
Novel cytidine deaminase
|
|
PT1176195E
(pt)
|
1999-04-09 |
2013-07-18 |
Kyowa Hakko Kirin Co Ltd |
Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
|
|
SE9902056D0
(sv)
*
|
1999-06-03 |
1999-06-03 |
Active Biotech Ab |
An integrin heterodimer and an alpha subunit thereof
|
|
US6808902B1
(en)
|
1999-11-12 |
2004-10-26 |
Amgen Inc. |
Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
|
|
US20020035107A1
(en)
*
|
2000-06-20 |
2002-03-21 |
Stefan Henke |
Highly concentrated stable meloxicam solutions
|
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
|
US20020141970A1
(en)
*
|
2001-03-05 |
2002-10-03 |
Pettit Dean K. |
Stable aqueous solutions of granulocyte macrophage colony-stimulating factor
|
|
ATE412013T1
(de)
*
|
2001-04-05 |
2008-11-15 |
Immuno Biological Lab Co Ltd |
Anti-osteopontin-antikörper und dessen verwendung
|
|
EP3192528A1
(en)
*
|
2002-02-14 |
2017-07-19 |
Chugai Seiyaku Kabushiki Kaisha |
Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer
|
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
|
EP2314603A3
(en)
|
2002-10-15 |
2011-05-18 |
Intercell AG |
Nucleic acids coding for adhesion factors of group B streptococcus, adhesion factors of group B streptococcus and futher uses thereof
|
|
MY150740A
(en)
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
|
EP2204190A1
(en)
|
2003-07-15 |
2010-07-07 |
Chugai Seiyaku Kabushiki Kaisha |
IgM production by transformed cells and methods for quantifying said IgM production
|
|
US8496930B2
(en)
|
2003-10-01 |
2013-07-30 |
Kyowa Hakko Kirin Co., Ltd |
Method of stabilizing antibody and stabilized solution-type antibody preparation
|
|
JP4762717B2
(ja)
|
2003-10-09 |
2011-08-31 |
中外製薬株式会社 |
ＩｇＭ高濃度安定化溶液
|
|
JP4671864B2
(ja)
*
|
2003-10-09 |
2011-04-20 |
中外製薬株式会社 |
タンパク質溶液の安定化方法
|
|
EP1712240B1
(en)
*
|
2003-12-25 |
2015-09-09 |
Kyowa Hakko Kirin Co., Ltd. |
Stable water-based medicinal preparation containing antibody
|
|
EP1568369A1
(en)
|
2004-02-23 |
2005-08-31 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of meloxicam for the treatment of respiratory diseases in pigs
|
|
SI1730191T1
(sl)
|
2004-03-30 |
2011-11-30 |
Glaxo Group Ltd |
Imunoglobulin-vezavni hOSM
|
|
TWI307630B
(en)
|
2004-07-01 |
2009-03-21 |
Glaxo Group Ltd |
Immunoglobulins
|
|
LT2620450T
(lt)
*
|
2005-03-08 |
2019-02-11 |
Pfizer Products Inc. |
Anti-ctla-4 antikūnų kompozicijos
|
|
EP1888637A2
(en)
*
|
2005-05-19 |
2008-02-20 |
Amgen Inc. |
Compositions and methods for increasing the stability of antibodies
|
|
WO2006138181A2
(en)
|
2005-06-14 |
2006-12-28 |
Amgen Inc. |
Self-buffering protein formulations
|
|
AR059066A1
(es)
|
2006-01-27 |
2008-03-12 |
Amgen Inc |
Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
|
|
US20110008282A1
(en)
*
|
2006-05-15 |
2011-01-13 |
Xbiotech, Inc. |
IL-1alpha immunization induces autoantibodies protective against atherosclerosis
|
|
SI2109623T1
(sl)
*
|
2006-05-22 |
2012-05-31 |
Xbiotech Inc |
Zdravljenje raka z anti il protitelesi
|
|
EP2081553B1
(en)
*
|
2006-10-06 |
2020-08-12 |
Amgen Inc. |
Stable antibody formulations
|
|
JP5623743B2
(ja)
*
|
2006-10-20 |
2014-11-12 |
アムジエン・インコーポレーテツド |
安定なポリペプチド製剤
|
|
AU2008205512B2
(en)
|
2007-01-16 |
2014-06-12 |
Abbvie Inc. |
Methods for treating psoriasis
|
|
NZ598881A
(en)
*
|
2007-03-29 |
2013-11-29 |
Abbvie Inc |
Crystalline anti-human il-12 antibodies
|
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
|
BRPI0908715A2
(pt)
|
2008-03-18 |
2016-05-03 |
Abbott Lab |
métodos para tratamento da psoríase
|
|
PL2285409T3
(pl)
*
|
2008-05-30 |
2016-10-31 |
|
Przeciwciała il-1 alfa
|
|
CA2737056C
(en)
*
|
2008-09-12 |
2018-10-30 |
Xbiotech Inc. |
Targeting pathogenic monocytes
|
|
MX2011005672A
(es)
*
|
2008-11-28 |
2011-06-20 |
Abbott Lab |
Composiciones de anticuerpo estables y metodos para estabilizar a las mismas.
|
|
AR074777A1
(es)
|
2008-12-19 |
2011-02-09 |
Glaxo Group Ltd |
Proteinas de union a antigeno
|
|
GB0904355D0
(en)
*
|
2009-03-13 |
2009-04-29 |
Imp Innovations Ltd |
Biological materials and uses thereof
|
|
NZ595694A
(en)
*
|
2009-05-04 |
2013-09-27 |
Abbvie Biotechnology Ltd |
Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
|
|
AU2010291927A1
(en)
*
|
2009-09-14 |
2012-04-12 |
AbbVie Deutschland GmbH & Co. KG |
Methods for treating psoriasis
|
|
CN102573895A
(zh)
*
|
2009-09-24 |
2012-07-11 |
埃克斯生物科技公司 |
减少抗-抗体反应的方法、组合物和试剂盒
|
|
EP2495319B1
(en)
*
|
2009-10-21 |
2018-12-05 |
Hiroshima University |
Integrin alpha8beta1-specific monoclonal antibody
|
|
KR20130028055A
(ko)
|
2010-01-28 |
2013-03-18 |
글락소 그룹 리미티드 |
Ｃｄ １２７ 결합 단백질
|
|
US20120308564A1
(en)
|
2010-02-09 |
2012-12-06 |
Andrew Ian Bayliffe |
Treatment of a metabolic disorder
|
|
RS59830B1
(sr)
|
2010-03-01 |
2020-02-28 |
Bayer Healthcare Llc |
Optimizovana monoklonska antitela protiv inhibitora puta faktora tkiva (tfpi)
|
|
UA108227C2
(xx)
|
2010-03-03 |
2015-04-10 |
|
Антигензв'язуючий білок
|
|
AR081556A1
(es)
|
2010-06-03 |
2012-10-03 |
Glaxo Group Ltd |
Proteinas de union al antigeno humanizadas
|
|
ES2703774T3
(es)
|
2010-06-18 |
2019-03-12 |
Xbiotech Inc |
Tratamiento para la artritis
|
|
NZ607472A
(en)
|
2010-08-23 |
2014-09-26 |
Xbiotech Inc |
Treatment for neoplastic diseases
|
|
EP2444101A1
(en)
|
2010-10-21 |
2012-04-25 |
Universitätsklinikum Freiburg |
Selective targeting of the CD40L/Mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis
|
|
CN103458926B
(zh)
|
2010-11-11 |
2016-10-26 |
艾伯维生物技术有限公司 |
改进的高浓度抗TNF α 抗体液体制剂
|
|
US9724409B2
(en)
|
2011-04-01 |
2017-08-08 |
Xbiotech, Inc. |
Treatment of inflammatory skin disease
|
|
US9062106B2
(en)
|
2011-04-27 |
2015-06-23 |
Abbvie Inc. |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
|
MX356808B
(es)
|
2011-09-23 |
2018-06-14 |
Xbiotech Inc |
Uso de una composición farmacéutica que comprende un anticuerpo anti-il-1a para el tratamiento de la caquexia.
|
|
US9895437B2
(en)
|
2012-04-18 |
2018-02-20 |
Valneva Austria Gmbh |
Aluminum compounds for use in therapeutics and vaccines
|
|
WO2013158279A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Protein purification methods to reduce acidic species
|
|
WO2013158273A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Methods to modulate c-terminal lysine variant distribution
|
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
|
US9249182B2
(en)
|
2012-05-24 |
2016-02-02 |
Abbvie, Inc. |
Purification of antibodies using hydrophobic interaction chromatography
|
|
US8883979B2
(en)
|
2012-08-31 |
2014-11-11 |
Bayer Healthcare Llc |
Anti-prolactin receptor antibody formulations
|
|
US8613919B1
(en)
|
2012-08-31 |
2013-12-24 |
Bayer Healthcare, Llc |
High concentration antibody and protein formulations
|
|
US9592297B2
(en)
|
2012-08-31 |
2017-03-14 |
Bayer Healthcare Llc |
Antibody and protein formulations
|
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
|
KR20150043523A
(ko)
|
2012-09-02 |
2015-04-22 |
애브비 인코포레이티드 |
단백질 불균일성의 제어 방법
|
|
US9545441B2
(en)
|
2012-09-18 |
2017-01-17 |
Xbiotech, Inc. |
Treatment of diabetes
|
|
SG11201507230PA
(en)
|
2013-03-12 |
2015-10-29 |
Abbvie Inc |
Human antibodies that bind human tnf-alpha and methods of preparing the same
|
|
US8921526B2
(en)
|
2013-03-14 |
2014-12-30 |
Abbvie, Inc. |
Mutated anti-TNFα antibodies and methods of their use
|
|
WO2014151878A2
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
|
|
US10081673B2
(en)
*
|
2013-03-14 |
2018-09-25 |
Ffe Therapeutics Llc |
Compositions and methods for treating angiogenesis-related disorders
|
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
|
EP3052640A2
(en)
|
2013-10-04 |
2016-08-10 |
AbbVie Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
|
WO2015073884A2
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
|
WO2016059602A2
(en)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Methods of treating cancer and related compositions
|
|
MA42613A
(fr)
|
2015-08-13 |
2018-06-20 |
Amgen Inc |
Filtration en profondeur chargée de protéines de liaison à un antigène
|
|
WO2017049529A1
(en)
|
2015-09-24 |
2017-03-30 |
Innolife Co., Ltd. |
A pharmaceutical composition comprising a copper chelating tetramine and the use thereof
|
|
EP3582813A4
(en)
|
2017-02-16 |
2020-12-30 |
XBiotech, Inc |
TREATMENT OF SUPPURATIVE HIDRADENITIS
|
|
CN110408600A
(zh)
*
|
2018-12-10 |
2019-11-05 |
浙江工商大学 |
一株分泌抗重金属铜离子单克隆抗体的杂交瘤细胞株及其应用
|
|
CA3095679A1
(en)
|
2020-10-07 |
2022-04-07 |
Xbiotech Inc. |
True human antibody specific for interleuken 1 alpha (il-1a)
|
|
CA3095675A1
(en)
|
2020-10-07 |
2022-04-07 |
Xbiotech Inc. |
True human antibody specific for interleukin 1 alpha (il-1a)
|
|
CA3095740A1
(en)
|
2020-10-07 |
2022-04-07 |
Xbiotech Inc. |
True human antibody specific for interleukin alpha (il-1a)
|
|
CA3095676A1
(en)
|
2020-10-07 |
2022-04-07 |
Xbiotech Inc. |
True human antibody specific for interleukin 1 alpha (il-1a)
|